COVID Moonshot
Project developing antiviral drug
Follow COVID Moonshot on Notably News to receive short updates to your email — rarely!
| June 2023 | Projected start of Phase-1 clinical trials for the COVID Moonshot antiviral drug candidate targeting the Mpro protein of coronaviruses. |
| March 2022 | COVID Moonshot aims to select three pre-clinical candidates for potential antiviral treatments against COVID-19. |
| January 2021 | Unique compound design submissions reached 14,000, prompting the project to transition from a spontaneous virtual collaboration to a more organized network of specialized partners. |
| May 2020 | Over 4,600 design submissions for potential inhibitors received, significantly exceeding the project's initial expectations. |
| March 7 2020 | COVID Moonshot project launched with open data release and Twitter announcement, challenging chemists worldwide to design potential antiviral drug candidates. |
| January 26 2020 | Zihe Rao and Haitao Yang submitted a structure of SARS-CoV-2 main protease (Mpro) bound to an inhibitor to the Protein Data Bank, providing crucial early X-ray crystallography insights into the virus's key protein. |
| January 11 2020 | Edward C. Holmes of the University of Sydney publicly releases the virus genome with Zhang's permission. |
| January 5 2020 | Zhang and his team successfully sequence the virus from the sample and deposit its genome on GenBank, an international research database. |
| January 3 2020 | Chinese virologist Yong-Zhen Zhang of Fudan University receives a test sample from Wuhan, China containing patients with a pneumonia-like illness. |
This contents of the box above is based on material from the Wikipedia article COVID Moonshot, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.